There may be no clear winners once the dust settles on a patent interference case involving two marquee research universities and billions of dollars in licensing fees tied to a revolutionary gene-editing tool.

The University of California, Berkeley, and the Broad Institute at the Massachusetts Institute of Technology both laid out their arguments Tuesday in a case that seeks to determine which was the first to invent a technique known as CRISPR-Cas9 in multicellular organisms.